Introduction {#Sec1}
============

Ovarian cancer is a common gynaecological cancer; its mortality rate ranks first among gynaecological tumours and it poses a serious threat to human life and health \[[@CR1], [@CR2]\]. In most cases, ovarian cancer is usually detected in advanced stages, so even with advanced therapeutic strategies, such as targeted therapy, chemoradiotherapy, and combined chemotherapy, the overall 5-year survival rate of ovarian cancer is still poor \[[@CR3]--[@CR5]\]. Therefore, it is essential to explore the possible prognostic biomarkers of ovarian cancer.

As a key molecule of chromatin remodelling, BCL7A is involved in the process of carcinogenesis. BCL7A is expressed in the ovary, brain, lymph nodes and other tissues. The gene is located on chromosome 12q24.31, and 1 natural variant has been found so far. BCL7A plays an important role in human cancer. It has been found that Myc and IgH are directly involved in the three-way gene translocation of Burkitt lymphoma cell lines, which may contribute to the progression of Burkitt lymphoma \[[@CR6], [@CR7]\]. In addition, BCL7A was found to be highly methylated in patients with cutaneous T-cell lymphoma and was identified as a marker of a poor prognosis in early-stage cutaneous T-cell lymphoma patients \[[@CR8]\]. However, the role of BCL7A in ovarian cancer remains unclear.

To further evaluate the clinical significance of BCL7A in the prognosis of ovarian cancer patients, we examined the differential expression of BCL7A mRNA in ovarian cancer by exploring the Cancer Genome Atlas database (TCGA). The chi-square test and Fisher's exact test were used to evaluate the clinical correlation. Survival analysis and a Cox regression model were employed to identify the correlation between BCL7A and ovarian cancer patients' survival rate.

Results {#Sec2}
=======

Data overview {#Sec3}
-------------

BCL7A expression data and clinical features from the TCGA database, including age, lymphatic invasion, stage, histologic grade, subdivision, new type, longest dimension, sample type, vital status and BCL7A expression, are shown in Table [1](#Tab1){ref-type="table"}.Table 1The baseline information of ovarian cancer patients from TCGA databasecharacteristicsNumbers.of.cases\...age  \< 55113(36.69)  \> =55195(63.31)subdivision NA17(5.52) Bilateral212(68.83) Left37(12.01) Right42(13.64)stage NA2(0.65) I1(0.32) II22(7.14) III245(79.55) IV38(12.34)longest dimension large124(46.1) small145(53.9)lymphatic invasion NA180(58.44) NO44(14.29) YES84(27.27)histologic grade NA2(0.65) G11(0.32) G237(12.01) G3261(84.74) G41(0.32) GB2(0.65) GX4(1.3)sample type Primary Tumor303(98.38) Recurrent Tumor5(1.62)vital status DECEASED184(59.74) LIVING124(40.26)BCL7A high154(50) low154(50)

Differential expression of BCL7A in ovarian cancer {#Sec4}
--------------------------------------------------

Boxplots revealed that lower BCL7A expression was found in ovarian cancer tissues compared with normal ovarian tissues (Fig. [1](#Fig1){ref-type="fig"}). In addition, BCL7A expression gradually decreased with an increasing histologic grade.Fig. 1The different BCL7A expression levels shown in a boxplot. The differential expression of BCL7A in tumour vs normal tissues (**a**) and other groups according to stage (**b**), histologic grade (**c**), new type (**d**), vital status (**e**), lymphatic invasion (**f**), subdivision (**g**) and age (**h**)

We used the median of BCL7A expression as a cut-off to divide patients into a BCL7A high-expression group and a low-expression group, and there was no difference in the clinicopathological parameters between the two groups (Table [2](#Tab2){ref-type="table"}).Table 2The correlation between BCL7A mRNA expression and clinical parametersBCL7A mRNA expressionParameterVariableNhigh%low%χ2Pvalueage\< 5511357(37.01)56(36.36)01\> = 5519597(62.99)98(63.64)subdivisionBilateral212111(77.08)101(68.71)3.06530.216Left3717(11.81)20(13.61)Right4216(11.11)26(17.69)stageI11(0.65)0(0)2.83640.4175II2214(9.15)8(5.23)III245119(77.78)126(82.35)IV3819(12.42)19(12.42)longest dimensionlarge12467(49.26)57(42.86)0.86820.3515small14569(50.74)76(57.14)lymphatic invasionNO4419(31.15)25(37.31)0.29950.5842YES8442(68.85)42(62.69)histologic gradeG110(0)1(0.65)2.03090.8449G23718(11.76)19(12.42)G3261131(85.62)130(84.97)G411(0.65)0(0)GB21(0.65)1(0.65)GX42(1.31)2(1.31)sample typePrimary Tumor303152(98.7)151(98.05)01Recurrent Tumor52(1.3)3(1.95)vital statusDECEASED18489(57.79)95(61.69)0.33750.5613LIVING12465(42.21)59(38.31)

A decrease in BCL7A expression is associated with a poor overall survival of ovarian cancer {#Sec5}
-------------------------------------------------------------------------------------------

As shown in Fig. [2](#Fig2){ref-type="fig"}, patients with a shorter overall survival time had particularly low expression of BCL7A (*P* = 0.034), which was consistent with the results of subgroup analysis, especially for advanced stage (*P* = 0.012), G3 and G4 (*p* = 0.0097), young patients (*p* = 0.038) and older patients (*p* = 0.049).Fig. 2Survival analysis of BCL7A expression in terms of overall survival. Kaplan--Meier curves produced survival analysis (**a**) and subgroup analysis of early stage (**b**), advanced stage (**c**), histological grade G1/G2 (**d**) and G3/G4 (**e**), lymphatic invasion (**f**), non-lymphatic invasion (**g**), young patients (**h**) and older patients (**i**)

A univariate Cox model showed that age and BCL7A expression were two survival related variables. A multivariate Cox model suggested that low BCL7A expression was an independent risk factor for ovarian cancer patients' overall survival (HR = 1.52, *P* = 0.005, Table [3](#Tab3){ref-type="table"}).Table 3Univariate and Multivariate Cox analysis of overall survival in ovarian cancerParametersUnivariate analysisMultivariate analysisHazard.RatioCI95*P*valueHazard.RatioCI95*P*valueage1.631.19--2.240.0031.641.2--2.260.002subdivision0.840.67--1.040.101stage1.090.8--1.50.581longest dimension1.120.82--1.520.485lymphatic invasion1.020.85--1.230.798histologic grade1.120.88--1.420.349sample type0.430.11--1.730.235BCL7A1.511.13--2.030.0061.521.14--2.050.005

The decrease in BCL7A expression is associated with poor relapse-free survival in ovarian cancer {#Sec6}
------------------------------------------------------------------------------------------------

As shown in Fig. [3](#Fig3){ref-type="fig"}, patients with a shorter relapse-free survival time had particularly low expression of BCL7A (*P* = 0.067), which was consistent with the results of subgroup analysis, especially in advanced stage (*P* = 0.014), G3 and G4 (*p* = 0.0014), and young patients (*p* = 0.003).Fig. 3Survival analysis of BCL7A expression in terms of relapse-free survival. Kaplan--Meier curves produced survival analysis (**a**) and subgroup analyses of advanced stage (**b**), histological grade G3/G4 (**c**), older patients (**d**) and young patients (**e**)

A univariate Cox model showed that BCL7A expression was the only relapse related variable. A multivariate Cox model suggested that low BCL7A expression was an independent risk factor for ovarian cancer patients' relapse-free survival (HR = 3.65, *P* = 0.011, Table [4](#Tab4){ref-type="table"}).Table 4Univariate and Multivariate Cox analysis of relapse-free survival in ovarian cancerParametersUnivariate analysisMultivariate analysisHazard.RatioCI95*P*valueHazard.RatioCI95Pvalueage0.710.3--1.670.433subdivision0.920.34--2.480.875stage1.920.78--4.710.156longest dimension0.620.25--1.560.311lymphatic invasion00-Inf0.998histologic grade1.350.65--2.830.421sample type1.470.19--11.30.711BCL7A3.651.35--9.890.0113.651.35--9.890.011

Discussion {#Sec7}
==========

Although the research on gynaecological cancer treatment technology is developing rapidly, predicting the outcome of ovarian cancer is still obscure \[[@CR9]\]. So far, the treatment of ovarian cancer is mainly based on surgery and chemotherapy \[[@CR10], [@CR11]\]. Therefore, it is urgent to find novel biomarkers to predict the outcome of ovarian cancer, which can be used develop targeted therapy for ovarian cancer, especially in its early stages, to improve its survival rate and the patients' quality of life. In this study, we found that the overall survival time of ovarian cancer patients was shorter when BCL7A was expressed at low levels. A Cox regression model showed that low expression of BCL7A was an independent risk factor for a poor outcome of ovarian cancer patients.

BCL7A was originally cloned from the chromosome translocation of the Burkitt lymphoma cell line \[[@CR7]\] and it can interact with SWI/SNF components, suggesting that BCL7A participates in the progression of cancer cells by chromatin remodelling \[[@CR12]\]. Recent studies have found that BCL7A expression is increased in diffuse large B-cell lymphoma (DLL) \[[@CR13]\] but decreased in mycosis fungoides (MF) and peripheral T-cell lymphoma (PTCL) \[[@CR14], [@CR15]\]. Unlike these studies, we have found that BCL7A expression was downregulated in ovarian cancer tissues compared with normal ovarian tissues, which might be due to the different expression and functions of BCL7A in different tissues. In addition, the boxplots showed that the expression of BCL7A had no significant difference in regard to age, lymphatic invasion, stage, histologic grade, subdivision, new type, longest dimension, sample type, or vital status. Therefore, it is necessary to understand the role of BCL7A in ovarian cancer further.

BCL7A has been proven to have a close correlation with the prognosis of patients. Previous studies have found that early-stage cutaneous T-cell lymphoma patients with low expression of BCL7A were more likely to have a poor prognosis \[[@CR8]\]. However, the association between BCL7A and overall survival was previously unknown in ovarian cancer. In this work, we found that the overall survival time was significantly shorter when ovarian cancer patients had low BCL7A expression. In addition, subgroup analysis found the same phenomenon in advanced stage, G3 and G4, and young patient and older patient groups.

To the best of our knowledge, this is the first study to examine the prognostic value of BCL7A expression in ovarian cancer. Together with other studies on the functions of BCL7A, we have contributed to a better understanding of the role of BCL7A as well as a better possibility of achieving a precise prognosis. However, the underlying mechanism has not been completely explored. In the future, we will perform sophisticated vitro and vivo experiments to explore the mechanism in depth.

Conclusion {#Sec8}
==========

In conclusion, we generally focused on the prognostic value of BCL7A for ovarian cancer patients. Low BCL7A expression has been proven to be a distinct marker of patients with a poor prognosis. In the future, we plan to perform in vitro and in vivo experiments to explore the mechanism further.

Materials and methods {#Sec9}
=====================

Data sources {#Sec10}
------------

We have obtained currently available clinical and RNAseq data from both normal and cancerous ovarian tissues. Databases, including TCGA (<https://cancergenome.nih.gov/>) and GTEx ([www.gtexportal.org/](http://www.gtexportal.org/)), were utilized. Level 3 data were downloaded from the databases. This dataset shows the gene-level transcription estimates, as in log2(x + 1) transformed RSEM normalized counts. There is no existing ethical conflict because all data we used in this study are permitted to be used in research.

Data mining {#Sec11}
-----------

R (version 3.5.1) \[[@CR16]\] was used for data mining. The ggplot2 package \[[@CR17]\] was utilized to draw boxplots of clinical characteristics due to their expression variation. We used the median BCL7A expression as a cut-off to delineate the low vs high categories. The Chi-square test and Fisher's exact test were used for the evaluation of the possible clinical correlation between clinical features and BCL7A expression. Survival package \[[@CR18], [@CR19]\] was used to draw survival curves, followed by log-rank tests to examine the survival deviation. Correlative variables were selected by a univariate Cox model, while the multivariate Cox model evaluated the independence of BCL7A rather than other clinical characteristics.

The results shown here are partly based upon data generated by the TCGA Research Network: <https://www.cancer.gov/tcga>.
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